United Therapeutics Corporation (UTHR)
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics Shares Thrive
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.
United Therapeutics: Economics Support Compounding Ability
United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.
United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)
United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.
United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Andreas Argyrides – Oppenheimer Operator Good morning, everyone and welcome to the United Therapeutics Corporation Second Quarter 2024 Earnings Webcast. My name is Cole and I will be your conference operator today.
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $5.85 per share, missing the Zacks Consensus Estimate of $6.33 per share. This compares to earnings of $5.24 per share a year ago.
